
Dr Atri emphasizes importance of managing neuropsychiatric symptoms in patients with Alzheimer’s disease and drugs under development.
Dr Atri emphasizes importance of managing neuropsychiatric symptoms in patients with Alzheimer’s disease and drugs under development.
The vice dean for data science at Duke University School of Medicine spoke about the major disparities observed in models that assess stroke risk. [WATCH TIME: 4 minutes]
Drs Juliana Gurgel Giannetti and Rodrigo de Holanda Mendonça provide an overview of available treatments for spinal muscular atrophy in Brazil. / Drs Juliana Gurgel Giannetti and Rodrigo de Holanda Mendonça discutem tratamentos para atrofia muscular espinhal disponíveis no Brasil.
Drs Juliana Gurgel Giannetti and Rodrigo de Holanda Mendonça discuss genetic changes in spinal muscular atrophy and genetic screening in Brazil. / Drs Juliana Gurgel Giannetti and Rodrigo de Holanda Mendonça discutem mudanças genéticas em atrofia muscular espinhal e screening genético no Brasil.
Drs Juliana Gurgel Giannetti, Adriana Banzzatto Ortega and Marcelo Kerstenetzky discuss symptoms of spinal muscular atrophy and diagnosis and referral process in Brazil. / Drs Juliana Gurgel Giannetti, Adriana Banzzatto Ortega e Marcelo Kerstenetzky discutem sintomas da atrofia muscular espinhal, diagnóstico e processo de encaminhamento no Brasil.
Dr Rodrigo de Holanda Mendonça provides an overview of spinal muscular atrophy (SMA). / Dr Rodrigo de Holanda Mendonça dá uma visão geral sobre Atrofia Muscular Espinhal (AME).
Ahead of the 2023 MDA Conference, which will be held from March 19-22, 2023, in Dallas, Texas, the vice president of public policy and advocacy at the Muscular Dystrophy Association provided an overview of the current state of access and the need for more advocates in neuromuscular disease. [WATCH TIME: 14 minutes]
The vice dean for data science at Duke University School of Medicine talked about the main findings from his latest published study on stroke risk algorithms. [WATCH TIME: 3 minutes]
At the 2022 AES Conference, the Baldwin Keyes professor of neurology at Thomas Jefferson University talked about how clinicians and patients might define a seizure. [WATCH TIME: 3 minutes]
The director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center discussed the presentation of radiologically isolated syndrome and identifying candidates for treatment. [WATCH TIME: 4 minutes]
At the 2022 AES Conference, the Baldwin Keyes professor of neurology at Thomas Jefferson University, talked about what defines a ‘seizure’ and changing the terminology. [WATCH TIME: 5 minutes]
Neurology News Network for the week ending January 21, 2022. [WATCH TIME: 3 minutes]
The assistant professor in the Department of Neurology at the University of Wisconsin spoke about healthcare providers establishing trust with their patients and improving health equity. [WATCH TIME: 3 minutes]
The director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center discussed ARISE, the first-ever study to show disease-modifying effect in radiologically isolated syndrome. [WATCH TIME: 3 minutes]
The director of the Montefiore Einstein Center for the Aging Brain detailed the efforts being made to support individuals in underrepresented communities and raise awareness for cognitive decline. [WATCH TIME: 4 minutes]
Dr Cohen shares current treatment options for Alzheimer’s disease and how she manages these patients in her practice.
Dr Atri discusses considerations and suggestions for caring for patients with Alzheimer’s disease.
At the 2022 AES annual meeting, the assistant professor in the Department of Neurology at the University of Wisconsin talked about her presentation and the key actions for addressing health equity. [WATCH TIME: 4 minutes]
The scientific researcher and clinical manager, Icahn School of Medicine at Mount Sinai, spoke about the clinical models used to predict seizures in poststroke patients. [WATCH TIME: 4 minutes]
At the 2022 AES annual meeting, the associate professor at Harvard Medical School and neurologist at the Brigham and Women's Hospital talked about seizure frequency and insomnia. [WATCH TIME: 2 minutes]
The neuropsychologist at Rutgers University spoke about the benefits of using smartphone applications to remotely monitor patients based on her most recent published study. [WATCH TIME: 3 minutes]
The director of the Tuberous Sclerosis Clinic at Cincinnati Children’s provided insight on whether the timing and combination of certain therapeutics may impact the long-term care for patients with tuberous sclerosis complex. [WATCH TIME: 3 minutes]
The neuropsychologist at Rutgers University, in New Brunswick, New Jersey, spoke about her most recent published study on assessing keystrokes on a smartphone in patients with multiple sclerosis. [WATCH TIME: 4 minutes]
The director of the Headache Center at Allegheny Health Network discussed whole-body therapeutic approaches to chronic migraine, and the difficulties with finding an effective, long-term strategy. [WATCH TIME: 8 minutes]
At the 2022 AES Conference, the scientific researcher and clinical manager at the Icahn School of Medicine at Mount Sinai talked on seizure management with medication in poststroke patients. [WATCH TIME: 3 minutes]
The neurosurgeon at Allegheny Health Network detailed the potential for robotics in neurosurgery over the coming years, and the vast improvements in comfortability during these procedures. [WATCH TIME: 3 minutes]
Neurology News Network for the week ending January 14, 2022. [WATCH TIME: 4 minutes]
The behavioral neurologist and medical director of the Toronto Memory Program provided perspective on the steps the general public can take toward reducing the risk of Alzheimer disease and initiating treatment early when needed. [WATCH TIME: 4 minutes]
The associate professor at Harvard Medical School and neurologist at the Brigham and Women's Hospital shared the current research on rapid eye movement in sleep and seizures. [WATCH TIME: 3 minutes]
Dr. Cohen shares factors that may have contributed to the high failure rate of Alzheimer’s disease clinical trials thus far.